menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Breaking Down Barriers for PAH Patient Risk Assessment Through EHR Systems

Program Information
Recommended

Program Information

ReachMD Healthcare Image
RestartResume

Learn about an educational resource to help healthcare professionals implement the REVEAL 2.0 and REVEAL Lite 2 risk assessment calculators into electronic health record systems.

  • Sponsored by

  • Overview

    Helping patients with pulmonary arterial hypertension (PAH) achieve and maintain a low mortality risk status, which has been associated with improved outcomes, is an overall treatment goal,1,2 prompting the development of several tools to assess risk status in patients with PAH.3 Yet widespread clinical implementation of these tools to date is considered to be fraught with barriers.4 Could the implementation of the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 and REVEAL Lite 2 risk assessment tools into an electronic health record (EHR) system be helpful in overcoming those barriers? Dr. Abhijit Raval and patient coordinator Kelly Dickson join Dr. Randy Young to share more about the importance of standardized risk assessment and their experience implementing the REVEAL tools into their institution's EHR.

    Dr. Randy Young is a paid consultant for ReachMD, and Dr. Abhijit Raval and Kelly Dickson are paid consultants for the Janssen Pharmaceutical Companies of Johnson & Johnson.

    References:

    1. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67-119.
    2. Galiè N, McLaughlin VV, Rubin LJ, Simonneau G. An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019;53:1802148.
    3. Benza RL, Lohmueller LC, Kraisangka J, Kanwar M. Risk assessment in pulmonary arterial hypertension patients: the long and short of it. Advances in Pulmonary Hypertension. 2018;16(3):125-135.
    4. Wilson M, Keeley J, Kingman M, Wang J, Rogers F. Current clinical utilization of risk assessment tools in pulmonary arterial hypertension: a descriptive survey of facilitation strategies, patterns, and barriers to use in the United States. Pulm Circ. 2020;10:2045894020950186.

    © 2022 Actelion Pharmaceuticals US, Inc. All rights reserved. cp-255991v1 02/22

Schedule4 Dec 2022